Nuclidium highlights studies at EANM 2023

2023 05 12 20 31 1472 Vienna Sunset Aerial 400

Nuclidium noted that studies highlighting its programs will be presented at the upcoming European Association of Nuclear Medicine (EANM) 2023 meeting.

The meeting is being held in Vienna from 9-13 September and will include presentations of positive preclinical and clinical translational data for diagnostic candidates from three of Nuclidium's precision oncology programs; namely, its copper-based theranostic CuTrace programs targeting epithelial tumors (Kalios), neuroendocrine tumors (TraceNET), and prostate cancer (NuriPro).

The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation, the company said.

Full details on the presentations can be found here.

Page 1 of 1240
Next Page